Researchers from the University of São Paulo and Brazil’s National Institute for Translational Medicine have found that combining cannabidiol (CBD) with sodium nitroprusside (SNP) may help prevent schizophrenia-related symptoms.
In the study, which was published by the Brazillian Journal of Psychiatry, Wistar rats were given CBD, SNP, or a combination during early brain development. After inducing schizophrenia-like symptoms, researchers measured behaviors related to movement, memory, and motivation.
The results revealed notable differences between males and females: females displayed more hyperactivity and long-term memory problems, while males showed reduced motivation and short-term memory deficits.
Individually, CBD and SNP had limited protective effects, but when combined, they significantly reduced hyperactivity and memory impairments in both sexes. Statistical analysis showed that the combined treatment was particularly effective in females.
Researchers conclude by saying “This study provides the first preclinical evidence of sex-dependent prophylactic efficacy of CBD-SNP in a schizophrenia model, suggesting a promising therapeutic strategy.”
